Phase IIb - Tirasemtiv Clinical Trial

Company

Cytokinetics, Incorporated

Canadian Clinics Recruiting

Montreal Neurological Institute
Montreal, Quebec, Canada, H3A 2B4
Contact: Marc Lemieux 514-398-2667 marc.lemieux@mcgill.ca

McMaster University Medical Centre
Hamilton, Ontario, Canada, L8S 4K1
Contact: Joan Martin 905-521-2100 ext 75232 martinj@mcmaster.ca

Trial Phase

Phase IIb – examining safety and potential efficacy

Trial Name

BENEFIT-ALS

Drug Name

Tirasemtiv

Route of Administration

Oral

Summary

Tirasemtiv is a drug designed to increase muscle strength in response to signals from the brain through the motor neurons. It also decreases the rate of muscle fatigue. As motor neurons degenerate in ALS, the connection to the muscle is weakened and eventually lost. During the stage of weakening, the hope is that Tirasemtiv can maintain normal muscle function for a longer period of time by making the muscles more sensitive to lower level neuronal signals. Tirasemtiv is considered a skeletal muscle activator.